MENU
ERAS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

ERAS stock forecast, quote, news & analysis

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers... Show more

ERAS
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
A.I.Advisor
a Summary for ERAS with price predictions
Sep 23, 2026

ERAS's RSI Oscillator stoops into oversold zone

The RSI Indicator for ERAS moved into overbought territory on September 23, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in 212 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

ERAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ERAS as a result. In 83 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The Moving Average Convergence Divergence Histogram (MACD) for ERAS turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 48 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

ERAS moved below its 50-day moving average on August 28, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ERAS crossed bearishly below the 50-day moving average on August 31, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for ERAS entered a downward trend on August 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.477) is normal, around the industry mean (26.046). P/E Ratio (0.000) is within average values for comparable stocks, (40.021). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.064). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (436.793).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.25B. The market cap for tickers in the group ranges from 58 to 130.87B. VRTX holds the highest valuation in this group at 130.87B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was 7%. JAGX experienced the highest price growth at 155%, while LGVN experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 33%. For the same stocks of the Industry, the average monthly volume growth was 104% and the average quarterly volume growth was 25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 58
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: -10 (-100 ... +100)
View a ticker or compare two or three
ERAS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
3115 Merryfield Row
Phone
+1 858 465-6511
Employees
103
Web
https://www.erasca.com
ERAS's RSI Oscillator stoops into oversold zone